US drug industry group defends price of Gilead hepatitis drugReuters IndiaMerck and Bristol-Myers presented new hepatitis C data on Thursday at a major liver disease meeting in London [ID:nL2N0N12E2] [ID:nL2N0N12BT]. Gilead, AbbVie and others will also…
Pfizer Inc. (NYSE:PFE): Potential New Oncology Therapy – BasicsMedia
Pfizer Inc. (NYSE:PFE): Potential New Oncology TherapyBasicsMediaIts other blockbuster drug Viagra is also attracting generic manufacturers and the company recently sued a company, Torrent Pharmaceuticals, based in India. Pfizer Inc. (NYSE:PFE) has rep…
Firefighters host annual blood drive in honor of Tyler Seddon – Warwick Beacon
|
Firefighters host annual blood drive in honor of Tyler Seddon
Warwick Beacon Legislation was passed that Rhode Island, Massachusetts, Connecticut and New Hampshire health insurance companies are required to cover the $112 cost for HLA typing and processing. Once the process is completed, a potential donor’s HLA type is … |
Managing Asthma: The Pharmacist's Role – Pharmacy Times
|
Managing Asthma: The Pharmacist’s Role
Pharmacy Times According to the NAEPP, current guidelines recommend long-term treatment with inhaled corticosteroids because they are very effective in decreasing airway inflammation compared with any other single long-term control medication. 10-12 Using a … |
Airman saves mother's life with organ donation – Air Force Link
|
Airman saves mother’s life with organ donation
Air Force Link Airman 1st Class Amber Davenport poses for a photo April 2, 2014, at Minot Air Force Base, N.D. Davenport recently donated a kidney to her mother, who had a life-threatening kidney disease. Davenport is a 5th Bomb Wing knowledge operations manager. |
Natco seeks to block Gilead's hepatitis C drug patent in India: source – Reuters
Economic Times |
Natco seeks to block Gilead’s hepatitis C drug patent in India: source
Reuters Gilead, whose medicine has been hailed by doctors as a breakthrough in treating the liver-destroying disease, has come under fire over its product’s $1,000 per pill price tag in the United States. India’s patent laws allow a third party to dispute the … WHO joins clamour to make new hepatitis C pills affordableDaily News & Analysis Gilead aims to license hepatitis C drug to 3-4 Indian firmsReuters India US drug industry group defends price of Gilead hepatitis drugChicago Tribune (blog) USTrade Voice –Businessweek all 222 news articles » |
Optimism associated with lower risk of heart failure, study says – Times of India
|
Optimism associated with lower risk of heart failure, study says
Times of India MUMBAI: Researchers from the University of Michigan and Harvard University found that optimism — an expectation that good things will happen — among people age 50 and older significantly reduced their risk of heart failure. Compared to the least … |
Natco seeks to block Gilead's hepatitis C drug patent in India: source – Reuters UK
|
Natco seeks to block Gilead’s hepatitis C drug patent in India: source
Reuters UK Gilead, whose medicine has been hailed by doctors as a breakthrough in treating the liver-destroying disease, has come under fire over its product’s $1,000 per pill price tag in the United States. India’s patent laws allow a third party to dispute the … |
Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are … – PR Newswire (press release)
|
Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are …
PR Newswire (press release) It is expected that these agents will be added to rituximab-containing regimens, such as bendamustine (Teva Pharmaceutical Industries’ Treanda, Mundipharma’s Ribomustin/Levact, Symbio Pharmaceuticals/Eisai’s Treakisym) in combination with rituximab, … |
Drug a dud for diastolic heart failure – ScienceBlog.com (blog)
Drug a dud for diastolic heart failureScienceBlog.com (blog)A drug that blocks the action of a key hormone did not significantly improve a set of cardiovascular outcomes for patients with diastolic heart failure, a condition in which the heart is stiff…